Compare Deckers Outdoor Corp (DECK) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs ResMed Inc. — how do they compare? Deckers Outdoor Corp trades at $82.97 (market cap $11.24B), while ResMed Inc. trades at $228.81 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 2.8× Deckers Outdoor Corp's market cap, and ResMed Inc. pays a 1.16% dividend while Deckers Outdoor Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and ResMed Inc. for 51 Days on average.
| DECK | RMD | |
|---|---|---|
Market Cap | $11.24B | $31.89B |
Volume | 3,010,945 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $277.88 |
52-Week Low | $77.51 | $182.82 |
Typical Hold Time | 71 Days | 51 Days |
Enterprise Value | $10.11B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers (DECK) trades at $82.15, up 2.2% with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats, 19.4% net margin, and robust revenue growth from $3.2B in 2022 to $5.0B in 2025. Recent news highlights HOKA and UGG brand momentum driving investor optimism. Technical indicators show the stock trading near resistance at $82 with support at $79.
DECK presents compelling value with a P/E of 11.7x below industry averages and analyst consensus target of $117 suggesting 43% upside. Risks include competitive pressures in footwear and potential macroeconomic headwinds affecting consumer discretionary spending. The strong cash flow generation and brand strength support continued growth potential.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
